Citigroup Inc. Sells 7,201 Shares of Haleon plc (NYSE:HLN)

Citigroup Inc. trimmed its position in Haleon plc (NYSE:HLN) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,035,789 shares of the company’s stock after selling 7,201 shares during the quarter. Citigroup Inc.’s holdings in Haleon were worth $10,959,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in HLN. AE Wealth Management LLC lifted its stake in Haleon by 6.1% in the second quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock worth $159,000 after purchasing an additional 1,098 shares during the last quarter. Cardinal Capital Management boosted its holdings in shares of Haleon by 2.5% during the 2nd quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock valued at $382,000 after acquiring an additional 1,140 shares during the last quarter. Lake Street Advisors Group LLC boosted its holdings in Haleon by 5.4% in the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company’s stock worth $237,000 after purchasing an additional 1,143 shares during the last quarter. Endowment Wealth Management Inc. boosted its position in Haleon by 9.9% in the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock worth $106,000 after purchasing an additional 1,161 shares during the last quarter. Finally, Portside Wealth Group LLC boosted its holdings in shares of Haleon by 2.7% in the second quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock worth $372,000 after buying an additional 1,182 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

NYSE:HLN opened at $9.72 on Friday. The company has a market cap of $44.00 billion, a price-to-earnings ratio of 28.59, a PEG ratio of 2.89 and a beta of 0.30. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The stock’s 50 day simple moving average is $9.95 and its two-hundred day simple moving average is $9.41. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Morgan Stanley upped their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Berenberg Bank assumed coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a “buy” rating for the company. Finally, UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Haleon presently has an average rating of “Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.